|
Company:
|
DENALI THERAPEUTICS INC. (DNLI)
|
|
Form Type:
|
4
|
|
Filing Date:
|
2/15/2022
|
|
CIK:
|
0001714899
|
|
Address:
|
161 OYSTER POINT BLVD.
|
|
City, State, Zip:
|
SOUTH SAN FRANCISCO, California 94080
|
|
Telephone:
|
(650) 866-8548
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$38.11
|
Change:
-0.37 (-0.96%)
|
Trade Time:
Aug 12
|
Market Cap:
$4.69B
|
|
|
|
|
|
|
Description of Business
|
|
Our goal is to discover, develop and deliver therapeutics to defeat
degeneration.
Neurodegeneration represents one of the most significant unmet medical needs of
our time, with few effective therapeutic options available for patients with
neurodegenerative diseases. Recent genetic insights are revealing the underlying
biology of neurodegeneration and potential drug targets while enabling better
patient selection, similar to how genetic insights have transformed the field of
oncology.
Our scientific strategy is guided by three overarching principles that we
believe will significantly increase the probability of success and accelerate
the timing to bring effective therapeutics to patients with neurodegenerative
diseases:
Genetic Pathway Potential - We select our therapeutic targets and disease
pathways based on studies that link human genetic variation to the risk of
developing a neurodegenerative disease.
|
|
|
|